[A19-45] Ribociclib (breast cancer; combination with fulvestrant) - Addendum to Commission A19-06
Last updated 04.07.2019
Project no.:
A19-45
Commission:
Commission awarded on 27.05.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
Patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer
Result of dossier assessment:
Conclusion of dossier assessment A19-06 unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-06 | Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-46 | Ribociclib (breast cancer; combination with an aromatase inhibitor) - Addendum to Commission A19-06 | Commission completed |
Federal Joint Committee (G-BA)
2019-07-04 A G-BA decision was published.